Tramadol Hydrochloride Tablet, Extended Release
Product Images NDC 76420-536

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 76420-536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-1 (Image 01)

Chemical structure diagram of Tramadol Hydrochloride, showing its molecular framework including a methoxyphenyl group, cyclohexane ring, and methyl-substituted amino group with associated hydrochloride (HCl).*

FDA Label Image

Image-2 (Image 02)

A pharmacokinetic profile graph showing Tramadol concentration (ng/mL) over 24 hours. It compares Tramadol Hydrochloride Extended-Release Tablets, 200 mg once daily, with Tramadol Hydrochloride Tablets, 50 mg every 6 hours, using solid and open circle markers respectively.*

FDA Label Image

Image-3 (Image 03)

A line graph comparing M1 metabolite concentration (ng/mL) over a 24-hour period for two Tramadol Hydrochloride tablet formulations. One line represents Extended-Release Tablets, 200 mg once daily, and the other represents 50 mg tablets taken every 6 hours. The x-axis shows time in hours, and the y-axis shows M1 concentration.*

FDA Label Image

Image-4 (Image 04)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 023 WOMAC Pain Responder Analysis' showing the percent of patients achieving response across varying response thresholds (percent improvement from baseline). It compares 100 mg, 200 mg, 300 mg, and 400 mg dosages of tramadol hydrochloride extended-release tablets with placebo, illustrating patient response rates decreasing as the response threshold increases.*

FDA Label Image

Image-5 (Image 05)

A line chart titled 'Tramadol Hydrochloride Extended-Release Tablets Study 015 Arthritis Pain Intensity VAS Responder Analysis' showing the percentage of patients achieving various response thresholds of pain improvement. The x-axis represents the response threshold as percent improvement from baseline (0 to 100%), and the y-axis represents the percent of patients achieving response (0 to 60%). Two lines compare Tramadol Hydrochloride Extended-Release Tablets and placebo across different thresholds, with tramadol showing higher patient response percentages at most thresholds.*

FDA Label Image

Image-6 (Image 06)

Packaging labels for Tramadol HCl ER Tablets, USP 100 mg extended-release tablets in quantities of 30, 60, and 90. The labels show Enovachem Pharmaceuticals as the releaser and packager, with manufacturing done for Lupin Pharmaceuticals, Inc. Each label includes NDC numbers (76420-536-30, 76420-536-60, 76420-536-90), description of the tablet appearance, and storage instructions.*

FDA Label Image

Image-7 (Image 07)

Packaging labels for Tramadol HCl ER Tablets, USP 200 mg extended-release oral tablets. The labels display quantities of 30, 60, and 90 tablets. Packaged by Enovachem Pharmaceuticals for Lupin Pharmaceuticals, each label includes the NDC codes 76420-537-30, 76420-537-60, and 76420-537-90 respectively, drug status CIV, and storage instructions at 20-25°C (68-77°F).*

FDA Label Image

Image-8 (Image 08)

Packaging labels for Tramadol HCl ER Tablets, USP 300 mg manufactured for Lupin Pharmaceuticals, Inc. by Enovachem Pharmaceuticals. Labels show three package sizes: 30 tablets (NDC 76420-538-30), 60 tablets (NDC 76420-538-60), and 90 tablets (NDC 76420-538-90). Tablets are described as white to off-white, circular, biconvex with beveled edges. Labels include drug status as Schedule CIV and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.